Adaptive Biotechnologies Corporation Stock
Equities
ADPT
US00650F1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.61 USD | -7.44% | +4.64% | -26.33% |
Financials (USD)
Sales 2024 * | 170M | Sales 2025 * | 209M | Capitalization | 532M |
---|---|---|---|---|---|
Net income 2024 * | -189M | Net income 2025 * | -149M | EV / Sales 2024 * | 3.04 x |
Net cash position 2024 * | 14.91M | Net cash position 2025 * | 7.88M | EV / Sales 2025 * | 2.51 x |
P/E ratio 2024 * |
-2.81
x | P/E ratio 2025 * |
-3.42
x | Employees | 709 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.9% |
Latest transcript on Adaptive Biotechnologies Corporation
1 day | -7.44% | ||
1 week | +4.64% | ||
Current month | +4.64% | ||
1 month | +13.52% | ||
3 months | -1.10% | ||
6 months | -23.35% | ||
Current year | -26.33% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Robins
FOU | Founder | 51 | 09-09-07 |
Chad Robins
CEO | Chief Executive Officer | 49 | 09-09-07 |
Kyle Piskel
DFI | Director of Finance/CFO | 40 | 21-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 13-01-31 |
Peter Neupert
BRD | Director/Board Member | 68 | 13-12-31 |
Michael Pellini
BRD | Director/Board Member | 58 | 18-02-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 3.61 | -7.44% | 1,449,572 |
24-06-06 | 3.9 | +1.56% | 1,167,367 |
24-06-05 | 3.84 | +13.27% | 2,296,003 |
24-06-04 | 3.39 | +2.42% | 2,033,249 |
24-06-03 | 3.31 | -4.06% | 1,612,814 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.33% | 532M | |
-41.97% | 7.92B | |
+5.99% | 3.51B | |
-4.31% | 2.18B | |
-21.69% | 1.97B | |
-24.94% | 1.58B | |
+31.45% | 1.14B | |
+26.75% | 792M | |
-9.83% | 690M | |
+3.38% | 303M |
- Stock Market
- Equities
- ADPT Stock